Clinical Trials Logo

Electronic Cigarette Use clinical trials

View clinical trials related to Electronic Cigarette Use.

Filter by:

NCT ID: NCT04613609 Completed - Clinical trials for Electronic Cigarette Use

Vaporized Nicotine and Autonomic Control

Start date: April 1, 2018
Phase: Early Phase 1
Study type: Interventional

E-cigarettes are marketed as an alternative to smoking for those who want to decrease the health risks of tobacco. Tobacco cigarettes increase heart rate (HR) and arterial pressure, while reducing muscle sympathetic nerve activity (MSNA) through sympathetic baroreflex inhibition. The acute effects of e-cigarettes on arterial pressure and MSNA have not been reported: our purpose was to clarify this issue. Using a randomized crossover design, participants inhaled on a JUUL containing nicotine (59 mg/ml) and a similar placebo e-cigarette (0 mg/ml).

NCT ID: NCT04450537 Completed - Vaping Clinical Trials

PACE Vape Messaging Study

Start date: June 23, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effect of exposure to vape education messages on beliefs, perceptions, norms, and behaviors related to electronic vapor product use.

NCT ID: NCT04399031 Completed - Cigarette Smoking Clinical Trials

Effects of e-Cigarettes on Perceptions and Behavior - Substudy 1

Start date: December 1, 2019
Phase: N/A
Study type: Interventional

This project will assess the ways in which e-cigarette product diversity impacts the user experience to inform potential regulations by identifying product characteristics that may: (1) put young adults at risk for tobacco product use; and (2) facilitate adult smokers switching to e-cigarettes. There are three primary objectives to the study: (1) Determine which dimensions of e-cigarette product diversity differentially affect product appeal in the overall population of tobacco product users as well as affect product appeal across young adult e-cigarette users and middle-age/older adult smokers; (2) Determine which dimensions of e-cigarette product diversity differentially affect product appeal in the overall population of tobacco product users as well as affect abuse liability in young adult e-cigarette users and the ability to resist smoking in adult smokers; (3) Determine the affect of product characteristics on e-cigarette nicotine delivery profile. For this substudy, young adult vapers (N=100) and adult smokers (N=100) will attend one laboratory session in which they will self-administer e-cigarette products varied according to within-subject e-cigarette factors (e.g., flavor, nicotine formulation).

NCT ID: NCT04378907 Completed - Clinical trials for Electronic Cigarette Use

Assessing Electronic Cigarette Nicotine Flux

Start date: January 5, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine differences in nicotine delivery, use behavior, carbon monoxide delivery, subjective effects, and physiological effects, when cigarette smokers use an electronic cigarette with constant device settings and different e-liquid concentrations.

NCT ID: NCT04332926 Completed - Clinical trials for Electronic Cigarette Use

Effects of E-Cigarette Nicotine Content in Smokers (Nicotine Flux Study)

Start date: January 5, 2021
Phase: N/A
Study type: Interventional

This study aims to better understand how e-cigarettes (ECIG) nicotine flux impacts several behavioral economic measures of abuse liability.

NCT ID: NCT04316234 Completed - Clinical trials for Electronic Cigarette Use

Acute Health Effects of Passive Vape Among COPD Patients

PASVAP
Start date: March 1, 2017
Phase: N/A
Study type: Interventional

The use of e-cigarettes is often permitted in otherwise smoke-free areas causing passive vape exposure for present individuals. Little is known about the potential adverse health effects of passive vape, and people with respiratory diseases may be more susceptible. The aim of the present study was to investigate local and systemic effects of short-term passive exposure to vape from e-cigarettes among patients with mild or moderate chronic obstructive pulmonary disease COPD in a randomized controlled double-blinded cross-over study.

NCT ID: NCT04271371 Completed - Smoking Clinical Trials

Preventing Relapse to Smoking Among Prisoners After Release

PROSPER
Start date: August 8, 2019
Phase:
Study type: Observational

Prisoners experience huge health inequalities, and their exceptionally high smoking prevalence (five times the national average) contributes significantly to their high mortality. Since the introduction of smoke-free polices across Her Majesty's Prison and Probation Service (HMPPS) in England and Wales, prisoners are now obliged to abstain from smoking while held in prison. This represents a unique opportunity to promote lifelong cessation in this highly disadvantaged and marginalised group. However, evidence suggests most prisoners intend to resume smoking as soon as possible after release. A systematic review of prison smoke-free polices worldwide concluded that there was a need for new research to identify effective strategies to reduce relapse in these individuals.

NCT ID: NCT04192032 Completed - Clinical trials for Electronic Cigarette Use

Assessing the Effect of Flavor on ENDS Users' Experiences and Exposures

Start date: November 15, 2018
Phase: N/A
Study type: Interventional

Recently, Maziak established a clinical lab at FIU to test the potential of waterpipe tobacco flavor regulation by the FDA. Given the importance of flavors on adolescent ENDS uptake and use, this lab is equipped to study the impact of flavor manipulations among adolescent ENDS users. In this study will recruit 80 young (18-24) JUUL users, in a 2x2 cross over lab study where in one condition they will use their JUUL preferred flavor and the other JUUL standard tobacco flavor. Our aims are to; Aim 1: Compare satisfaction, withdrawal suppression, and harm perception between tobacco-flavored and preferred flavor JUUL. This analysis will reveal the extent to which preferred flavor contributes to smoking satisfaction, withdrawal and craving suppression, and harm perception, compared to the standard tobacco flavor. Aim 2: Compare puff topography and plasma nicotine levels between tobacco-flavored and preferred flavor JUUL. This analysis will examine the extent to which preferred flavor contributes to puffing behavior and toxicant exposure compared to the standard tobacco flavor. Aim 3: Compare exhaled breath condensate (EBC) between tobacco-flavored and preferred flavor JUUL. This analysis will be the first to examine exposure to toxic aldehydes (formaldehyde, acetaldehyde, acrolein, benzaldehyde, and propionaldehyde) produced when using preferred flavor compared to the standard tobacco flavor. Utilizing powerful clinical lab methods, this study will provide a broad testing of the effect of flavor manipulation on college-aged JUUL users, and provide experimental evidence about the potential of flavor-limitation policies on young ENDS users in the US.

NCT ID: NCT04151784 Completed - Pulmonary Disease Clinical Trials

Factors That Impact the Relationship Between Pulmonary Status and Susceptibility to Electronic Cigarette Use

Start date: January 1, 2020
Phase:
Study type: Observational

The purpose of the study is to explores various psycho-social, physiological, cognitive, behavioral, and environmental factors that may affect the association between pulmonary status and Susceptibility to Electronic Cigarette Use

NCT ID: NCT04143256 Completed - Tobacco Use Clinical Trials

Evaluating Selected Constituents in the Exhaled Breath Samples

Start date: October 3, 2019
Phase: N/A
Study type: Interventional

An Open-Label, Multi-Center Study to Evaluate Selected Constituents in the Exhaled Breath Samples From the Use of JUUL Nicotine Salt Pod System Product (5% and 3% Virginia Tobacco, Mint, Mango, Menthol) Users and Conventional Cigarettes (Non-Menthol and Menthol Flavors)